All Articles tagged metastatic breast cancer
- Oncology
October 21, 2015 EDT We compare the cost-effectiveness of eribulin in Spain as a second-line treatment for HER2-negative MBC with its current status as a third-line treatment for patients who have received capecitabine.
- Methodology and Healthcare Policy
February 14, 2015 EDT This paper looks at different techniques that can be used to extrapolate trial data, as well as criteria that should be used to select the most appropriate technique.